Xlife - INITIATION - European IP Commercialisation Play (TP CHF47, 50 pgs)
Xlife is an IP commercialisation company but with a strong focus on CDMO’s/CRO’s and A.I. based Healthcare assets. We believe they have an exciting opportunity to generate superior returns given management’s extensive European network. Whilst there has been limited success from European Biotech, Europe has a strong track record in developing and growing highly successful CDMO & CRO companies. Xlife project co’s are skewed towards the healthcare services space. Xlife was formed in 2019, so there have yet to be any exits to showcase the returns profile, but the early signs are that some holdings have increased more than 6x. We see ~50% upside to the current valuation and significantly more in the mid-term.For access to the full note, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.